Skip to main content

Christopher Viehbacher

Equibles does not estimate personal net worth.

Get an email with a short summary when Biogen Inc. publishes a filing, an earnings call transcript or a press release.

Get BIIB alerts

About Christopher Viehbacher

Christopher Viehbacher is recorded as Board Member at Biogen Inc. (BIIB) since January 1, 2022 and CEO at Biogen Inc. (BIIB). The proxy statement of Biogen Inc. reports total compensation of $23,646,004 for Christopher Viehbacher in fiscal 2025, including a base salary of $1,727,885. Disclosed compensation is on record for 4 fiscal years. Christopher Viehbacher has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Biogen Inc. on July 29, 2026. Biogen Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Biogen Inc. includes Christopher A. Viehbacher (CEO and Board Member), Caroline D. Dorsa (Chairman), Michael R. McDonnell (CFO) and 7 others.

Christopher Viehbacher on recent calls

“And just the U.S. is actually one of the last countries to launch actually unusually. So Japan, where we launched earlier as in Europe, that's where actually we're seeing, particularly in Germany, seeing a reversal of the trend of switching to oral therapy and some trending back.”
CEO, Biogen Inc. Q2 FY2026 Earnings Call ·
“So we've had a very strong start to the year. And, you know, I was thinking about where we have been as a company. In 2023, we had just completed four years of declining revenue and profit.”
CEO, Biogen Inc. Q1 FY2026 Earnings Call ·
“We finished the year strongly with a very good fourth quarter, and I think finished the year in a very satisfactory manner.”
CEO, Biogen Inc. Q4 FY2025 Earnings Call ·
“I've got my current head of IR and my prior head of IR from Sanofi here with me to make sure I don't screw up. All right, so exciting year at Biogen. You know, we've been on a long journey.”
CEO, Biogen to Present at the 44th Annual J.P. Morgan Healthcare Conference ·
“I believe we've achieved a very strong third quarter. I am particularly pleased to report a 67% year-on-year growth in our launch products during this quarter. These launch products have more than compensated for the MS decline on a year-to-date basis.”
CEO, Biogen Inc. Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Biogen Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Biogen Inc. (BIIB) $1,727,885 $23,646,004
2024 Biogen Inc. (BIIB) $1,600,000 $24,166,665
2023 Biogen Inc. (BIIB) $1,600,000 $4,069,913
2022 Biogen Inc. (BIIB) $153,846 $30,488,593

Recent activity